Table 3.
Summary of meta-analysis results of modifiable factors for mortality in non-HIV-related Pneumocystis pneumonia.
| Factors | No. study | Sample (n) | Heterogeneity test | Effects model | OR/MD (95% CI) | P-value | |
|---|---|---|---|---|---|---|---|
| P-value | I2 (%) | ||||||
| Cytomegalovirus | 5 | 287 | 0.21 | 32 | Fixed effects model | 3.59 (1.91–6.75) | <0.0001 |
| Pneumothorax | 6 | 340 | 0.45 | 0 | Fixed effects model | 2.55 (1.13–5.77) | 0.02 |
| PCP prophylaxis | 7 | 640 | 0.67 | 0 | Fixed effects model | 1.43 (0.75–2.71) | 0.28 |
| Corticosteroid after admission | 8 | 675 | 0.36 | 8 | Fixed effects model | 1.44 (0.94–2.22) | 0.1 |
| Invasive ventilation | 12 | 849 | 0.01 | 54 | Random effects model | 29.24 (13.09–65.33) | <0.00001 |
| Lactate dehydrogenase | 9 | 538 | 0.002 | 67 | Random effects model | 91.12 (1.16–181.09) | 0.05 |
| Albumin | 9 | 618 | <0.00001 | 88 | Random effects model | −0.18 (-0.46–0.10) | 0.22 |
| Lymphocyte count | 10 | 711 | 0.03 | 51 | Random effects model | −0.25 (-0.39−0.10) | 0.0008 |
| Time from onset of symptoms to treatment | 6 | 499 | 0.007 | 69 | Random effects model | 1.9 (-1.18–4.99) | 0.23 |
CI, confidence interval; MD, mean difference; OR, odds ratio; PCP, Pneumocystis pneumonia.